Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Refocus seeks US nod for presbyopia implant trials:

This article was originally published in Clinica

Executive Summary

Eye disorders medical device firm Refocus Group has filed an application with the US FDA to start phase II clinical trials of its implant system for treating presbyopia. Its scleral implants are implanted in the eye surgically, using a redesigned version of its scleral spacing procedure (SSP), which Refocus believes will simplify the surgical procedure and produce highly consistent outcomes. The Dallas, Texas company filed the clinical trial application together with its partner, CIBA Vision, the eye care unit of Novartis AG. CIBA Vision is seeking strategic alternatives for its surgical business unit.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT065359

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel